Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.

Oncologist · 2025 · PMC12284923 · PMID 40554667

Europe PMC DOI

hedged sentences

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

did not reach statistical significanceP = 0.087so close (0.05 < p ≤ 0.1)

7.17 months, 95% CI, 3.72-10.62), this difference did not reach statistical significance (HR 0.62, 95% CI, 0.35-1.08; log-rank P = 0.087; Figure 2B ).

also in 111,027 other papers

showed a trendno p-value reported

Although the median overall survival (OS) showed a trend toward being longer in the Cam-NP group (9.8 months, 95% CI, 7.32-12.28 vs. 7.17 months, 95% CI, 3.72-10.62), this difference did not reach statistical significance (HR 0.62, 95% CI, 0.35-1.08; log-rank P = 0.087; Figure 2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.